Hypoactive Sexual Desire Disorder (HSDD): Rare and Atypical Presentations

Why "Atypical" HSDD Gets Missed So Often

Most clinical discussions of HSDD center on a fairly narrow profile: a cisgender, partnered, perimenopausal woman with no acute medical history who reports gradual loss of interest in sex. That profile is real and common, but it accounts for only a portion of the women who actually meet diagnostic criteria for HSDD.

HSDD is defined by the DSM-5 as persistently or recurrently deficient or absent sexual fantasies and desire for sexual activity, causing marked distress, for at least six months. The distress criterion is what separates a normal variation in libido from a diagnosable condition. When that distress is present in an unexpected population, or when desire loss is framed as something else entirely, the diagnosis gets delayed or missed.

A 2021 analysis published in the Journal of Sexual Medicine estimated that approximately 10% of women meet full DSM-5 criteria for HSDD at any time point, yet fewer than 20% of affected women report ever discussing sexual concerns with a healthcare provider. The gap between prevalence and clinical recognition is sharpest in the atypical groups described below.

The WomanRx clinical team uses a four-axis framework for identifying atypical HSDD presentations. The axes are: (1) unexpected life stage, (2) underlying medical or surgical cause, (3) iatrogenic or medication-driven suppression, and (4) identity or relationship context that changes how desire is experienced and reported. Each axis is addressed below.

Axis 1: Unexpected Life Stages for HSDD

HSDD in Women Under 30

Low desire is frequently dismissed as "normal" in young women, especially if they are stressed, in early relationships, or using hormonal contraception. That dismissal is a clinical error.

A cross-sectional study of women aged 18 to 31 found that 8.9% met criteria for HSDD, with rates highest in women using combined oral contraceptives. The pill lowers free testosterone by raising sex hormone-binding globulin (SHBG), and SHBG levels can remain elevated for months after stopping oral contraceptives, a phenomenon sometimes called "post-pill HSDD" that has been documented in several small but replicable studies.

Young women with HSDD are also more likely to attribute their symptoms to relationship problems or personal failings rather than to a recognizable medical pattern. Screening them directly is the only reliable way to make the diagnosis.

Postpartum and Lactating Women

Postpartum HSDD is common yet almost never discussed in the context of the formal diagnosis. Desire suppression in this life stage has at least three overlapping mechanisms: a sharp postpartum drop in estrogen and testosterone, prolactin-mediated inhibition of GnRH (which blunts ovarian androgen output during lactation), and sleep deprivation altering dopamine signaling in the reward circuits that underlie spontaneous desire.

Rates of clinically significant sexual distress in the postpartum period range from 20% to 43% in studies using validated instruments, with the highest rates in exclusively breastfeeding women at three to six months postpartum.

The complication for clinicians is that some degree of reduced desire postpartum is biologically expected. The HSDD diagnosis applies when the woman is distressed by the change and when it persists beyond what she considers her personal baseline. Neither FDA-approved HSDD drug (flibanserin or bremelanotide) is recommended during lactation. Management at this life stage relies on education, optimizing sleep where possible, pelvic floor rehabilitation, and addressing co-occurring postpartum depression, which itself suppresses desire.

HSDD in Adolescents With Chronic Illness

This is among the least-studied presentations. Adolescents and young adults with conditions such as lupus, inflammatory bowel disease, juvenile rheumatoid arthritis, or type 1 diabetes carry a high burden of fatigue, pain, and immunosuppressant medications that collectively impair desire. Because sexual function is rarely asked about in pediatric-to-adult transition care, HSDD in this group is almost always missed entirely.

A 2019 review in the Journal of Adolescent Health noted that fewer than 5% of adolescent chronic illness clinics routinely screen for sexual dysfunction despite its documented prevalence in this population.

Axis 2: Medical and Surgical Causes That Don't Fit the Typical Story

HSDD After Cancer Treatment

Cancer survivorship presents one of the most under-addressed HSDD contexts in women's health. Chemotherapy, pelvic radiation, surgical menopause from bilateral oophorectomy, and aromatase inhibitor (AI) therapy each independently suppress desire through different mechanisms.

Surgical menopause from bilateral oophorectomy before age 45 removes roughly 50% of a premenopausal woman's circulating testosterone and essentially all of her estrogen overnight, producing rates of HSDD that exceed 50% in the first year post-surgery. The onset is abrupt, the severity is often greater than in natural menopause, and the distress is compounded by the cancer diagnosis itself.

Women on aromatase inhibitors for hormone-receptor-positive breast cancer face an additional challenge. AIs suppress estrogen to near-zero levels, and the resulting genitourinary syndrome of menopause (GSM) causes dyspareunia that further inhibits desire through a pain-avoidance cycle. The ATAC trial found that musculoskeletal symptoms and sexual dysfunction were significantly more frequent in the anastrozole arm than in tamoxifen users, yet sexual function endpoints are rarely the primary focus of oncology follow-up visits.

Systemic testosterone for HSDD in breast cancer survivors remains controversial because of theoretical estrogen conversion concerns, but a 2021 position statement from the International Society for the Study of Women's Sexual Health (ISSWSH) concluded that evidence does not currently demonstrate increased breast cancer risk from testosterone therapy at physiologic doses.

HSDD in Women With Autoimmune Disease

Lupus, multiple sclerosis (MS), rheumatoid arthritis, and Sjögren's syndrome all affect desire through several overlapping routes: inflammatory cytokines that act on hypothalamic reward circuits, fatigue, chronic pain, and corticosteroid use. Corticosteroids in particular suppress adrenal androgen production over time.

In a cohort study of women with MS, 63% reported low sexual desire as a current concern, compared with 25% of age-matched controls. MS-related HSDD has both a central component (demyelination of pathways involved in arousal) and a peripheral component (spasticity, fatigue, bladder dysfunction reducing sexual confidence).

HSDD After Traumatic Brain Injury or Hypothalamic Damage

Desire is centrally regulated. Any injury or lesion that disrupts the hypothalamic-pituitary axis can produce HSDD directly, separately from any emotional or psychological response to the injury. Women with traumatic brain injury (TBI), pituitary adenomas, craniopharyngiomas, or a history of cranial radiation are at risk. This is an area where the evidence base in women specifically is thin, and most data is extrapolated from mixed-sex TBI cohorts.

Axis 3: Iatrogenic and Medication-Driven HSDD

Iatrogenic HSDD is the presentation most often dismissed because the suppression is attributed to a necessary medication. Yet distress about low desire is just as real whether the cause is pharmacologic or not.

SSRIs and SNRIs

Selective serotonin reuptake inhibitors are the leading iatrogenic cause of HSDD in women of reproductive age. Serotonin excess suppresses dopaminergic signaling in the mesolimbic system, directly reducing spontaneous desire. A meta-analysis of 31 randomized trials found that sexual dysfunction rates with SSRIs ranged from 25% to 73%, with desire specifically affected in a majority of cases.

The clinical challenge is that the depression itself also suppresses desire. Parsing SSRI-induced HSDD from depression-driven HSDD requires timing: if desire was intact before starting the antidepressant and worsened within weeks of initiation, the drug is the more likely contributor. Options include dose reduction, switching to bupropion (which has a neutral-to-positive effect on desire), or adding low-dose bupropion as an adjunct. Bremelanotide has shown benefit in women with antidepressant-associated sexual dysfunction in small proof-of-concept studies, though this remains an off-label use.

Hormonal Contraception

As described above, combined oral contraceptives raise SHBG and lower free testosterone. One study found that women using low-dose ethinyl estradiol pills had mean free testosterone levels 61% lower than naturally cycling women. This is not a universal effect, but in susceptible women it produces clinically significant HSDD that may persist post-discontinuation.

Non-hormonal IUDs, progestin-only methods with lower systemic exposure (e.g., hormonal IUDs with levonorgestrel), and barrier methods do not carry the same SHBG-mediated risk, making contraceptive method review a practical first step in young women presenting with HSDD.

Opioids and Anticonvulsants

Chronic opioid use suppresses GnRH pulsatility, reducing LH, FSH, estrogen, and testosterone. Opioid-induced endocrinopathy is under-recognized in women with chronic pain conditions, who are also disproportionately affected by fibromyalgia and musculoskeletal disorders. Anticonvulsants, particularly enzyme-inducing agents like carbamazepine and phenytoin, increase SHBG and accelerate androgen metabolism, producing a functional androgen-deficiency state.

Axis 4: Identity and Relationship Contexts That Change the Clinical Picture

HSDD in Sexual Minority Women

Bisexual and lesbian women are less likely to be asked about sexual desire in clinical encounters framed around heterosexual partnered sex. Standard screening questions about "desire for sex with your partner" may not capture desire patterns in women who are not currently partnered, who have partners of the same sex, or who experience desire in non-partnered contexts.

A 2017 nationally representative survey found that lesbian and bisexual women reported sexual distress at rates comparable to heterosexual women but were significantly less likely to have been asked about sexual function by a healthcare provider. The absence of a question is not the same as absence of a problem.

HSDD in Transgender Women and Non-Binary Individuals

This is one of the least-studied areas in all of sexual medicine. Transgender women on gender-affirming hormone therapy (estrogen plus an antiandrogen) undergo deliberate testosterone suppression, which can produce HSDD in those who retain desire as a valued part of their gender experience. Non-binary individuals assigned female at birth may develop HSDD related to gender dysphoria, testosterone therapy, or the interaction between both.

Current HSDD diagnostic criteria use gender-neutral language in the DSM-5, which helps, but validated desire instruments were developed almost exclusively in cisgender women. Clinicians working with gender-diverse patients should use the validated instruments while acknowledging their limitations, and should ask directly about desire in the context the patient defines as meaningful.

HSDD in the Context of Asexuality

Not every woman with absent sexual desire has HSDD. Asexuality, defined as a stable, lifelong, non-distressing absence of sexual attraction, is a sexual orientation rather than a disorder. The distinction rests on the distress criterion: if a woman reports no desire and no distress about that absence, HSDD criteria are not met. Clinicians should ask about distress explicitly and should not assume that absent desire is inherently pathological.

The ISSWSH 2022 consensus document on women's sexual health terminology specifically addresses the asexuality-HSDD boundary and recommends that clinicians validate asexual identity before pursuing a dysfunction diagnosis.

How Atypical HSDD Presents Clinically: Signs to Watch For

Women with atypical HSDD often do not use the phrase "low libido" when they come to a clinical visit. They may describe:

• Feeling "numb" or emotionally flat (sometimes confused with anhedonia from depression)
• Saying yes to sex to avoid conflict, without any internal desire preceding the encounter (sometimes called "receptive only" or "duty sex")
• Noticing that desire is present in fantasy but absent with a current partner (situational HSDD)
• Reporting that orgasm is intact but the motivation to initiate sex is gone
• Describing desire loss as a new symptom after a specific medication start, surgery, or diagnosis

The Female Sexual Function Index (FSFI) desire subscale and the Decreased Sexual Desire Screener (DSDS) are both validated tools that take under five minutes to administer and can surface HSDD in populations where providers would not have thought to ask.

Situational HSDD, where desire is absent only with a specific partner or context but present in other situations, carries different diagnostic and therapeutic implications than generalized HSDD. Both are real presentations; the distinction matters because treatment targets differ. Relationship-specific HSDD responds better to couples-based sex therapy, while generalized HSDD is more likely to have a biological substrate.

Diagnostic Workup in Atypical Presentations

Laboratory Evaluation

Standard HSDD workup includes thyroid function (hypothyroidism directly suppresses desire), prolactin (hyperprolactinemia inhibits GnRH), total and free testosterone, SHBG, estradiol, and FSH. In women with suspected iatrogenic androgen suppression, measuring SHBG alongside free testosterone is more informative than total testosterone alone.

There is no testosterone threshold that defines HSDD. The Endocrine Society's 2019 guideline on testosterone therapy in women specifically states that there is no serum testosterone level that reliably diagnoses female sexual dysfunction, and that the diagnosis remains clinical. This is a critical point: a "normal" testosterone does not rule out HSDD, and a low testosterone does not confirm it without accompanying distress.

Psychological and Contextual Screening

A validated HSDD workup also includes screening for depression (PHQ-9), generalized anxiety (GAD-7), a brief trauma history, current relationship satisfaction, and body image concerns. In cancer survivors, assessing for post-traumatic distress and fear of cancer recurrence is relevant because both independently suppress desire.

Treatment Considerations Specific to Atypical Presentations

FDA-Approved Options and Their Limitations in Atypical Groups

Flibanserin (Addyi) is FDA-approved for premenopausal women with generalized acquired HSDD. In the three key VIOLET trials, flibanserin produced a statistically significant increase in satisfying sexual events and a reduction in distress compared to placebo, with mean increases of approximately 0.5 satisfying sexual events per month above placebo. The effect size is modest, and the drug requires alcohol avoidance because of a hypotension interaction. Flibanserin works centrally, increasing dopamine and norepinephrine while reducing serotonin in the prefrontal cortex.

Bremelanotide (Vyleesi) is a melanocortin receptor agonist given as a subcutaneous injection up to 45 minutes before anticipated sexual activity. In the RECONNECT trials, bremelanotide produced a statistically significant reduction in distress and improvement in desire compared to placebo, with nausea reported in approximately 40% of users as the most common adverse effect. Neither drug has been studied in postpartum women, cancer survivors, or transgender individuals.

Off-Label Testosterone Therapy

Transdermal testosterone at doses producing physiologic premenopausal female levels (approximately 150 to 300 mcg/day) is the most commonly used off-label approach for postmenopausal HSDD and for surgically menopausal women of any age. The Global Consensus Statement on testosterone therapy for women, published in 2019 and endorsed by multiple international societies including The Menopause Society, concluded that there is strong evidence supporting transdermal testosterone for postmenopausal women with HSDD. The evidence base for premenopausal women is smaller but growing.

Psychotherapy and Sex Therapy

Cognitive behavioral therapy (CBT) and mindfulness-based sex therapy have both shown benefit in women with HSDD across life stages. A randomized controlled trial by Brotto and colleagues found that a four-session mindfulness-based psychoeducational group significantly improved desire, arousal, and sexual distress in women with gynecologic cancer, making it a particularly relevant option in the cancer-survivor population where pharmacologic options are constrained.

Pregnancy, Lactation, and Contraception

Pregnancy and lactation are themselves atypical HSDD contexts, and both affect treatment options significantly.

During pregnancy: Neither flibanserin nor bremelanotide has adequate human safety data in pregnancy. The FDA label for flibanserin states that animal reproduction studies showed embryo-fetal toxicity at doses higher than the recommended human dose, and the drug should be discontinued if pregnancy is confirmed. Women of reproductive age taking flibanserin should use reliable contraception.

During lactation: Flibanserin is present in rat milk; human lactation data are absent. Bremelanotide lactation data are also absent. Both drugs should be avoided while breastfeeding. The LactMed database maintained by the National Institutes of Health does not list either drug as compatible with breastfeeding.

Testosterone in lactation: Low-dose transdermal testosterone use during breastfeeding has not been adequately studied. Theoretical concerns about infant androgen exposure exist, and most clinicians advise against it until breastfeeding is complete.

Contraception requirement: Because flibanserin requires alcohol avoidance and carries a CNS-depression risk profile that makes an unintended pregnancy complicated to manage, women taking it should be counseled about effective contraception, particularly if they are in the reproductive years where HSDD is present off-label.

For postpartum women distressed by HSDD, the most evidence-supported approaches are non-pharmacologic: pelvic floor physical therapy, psychoeducation about the hormonal physiology of lactation, CBT or sex therapy, and treatment of co-occurring postpartum depression with bupropion if an antidepressant is needed (given its neutral effect on desire compared to SSRIs).

Who This Is Right for, and Who Needs a Different Approach

This diagnosis fits women who:

• Report absent or markedly reduced desire, in any life stage, that has persisted for at least six months
• Experience personal distress about the change
• Do not have an exclusively relational explanation (though relationship factors often co-occur)
• Have ruled out or are simultaneously addressing conditions that suppress desire (hypothyroidism, depression, GSM)

A different approach is needed when:

• The absence of desire is non-distressing. This may reflect asexuality or a shift in priorities that does not require medical treatment.
• The low desire is entirely situational with one partner and absent only in that context. Couples therapy is the primary intervention.
• A reversible medication cause has not been addressed first. Stopping or switching the offending drug before adding a new one is sound clinical practice.
• The woman is pregnant or breastfeeding. FDA-approved HSDD drugs are not appropriate in this context.
• The woman has active, unstreated depression. Treating the mood disorder first often restores desire without specific HSDD treatment.

What Clinicians Ask Women They Shouldn't Have to Wait to Be Asked

Many women with HSDD wait for their provider to open the topic. Providers frequently wait for the patient to bring it up. Both parties wait, and the condition goes untreated for an average of 18 months. A single validated screening question, "In the past six months, have you been bothered by a lack of interest in sex?", takes approximately eight seconds to ask and can surface the diagnosis across every atypical group described in this article.

The ISSWSH recommends that sexual health screening be part of routine well-woman care at every life stage, and specifically calls out the postpartum visit, the cancer follow-up appointment, and the chronic disease management visit as high-yield moments where the question is rarely asked but almost always welcomed.